Product Description
Mechanisms of Action: VEGFR1 Inhibitor,VEGFR2 Inhibitor,VEGFR3 Inhibitor,PGFR Inhibitor,KITl Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Pleural Effusion|Pericardial Effusion|Pleural Cancer
Phase 2: Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Thyroid Cancer|Gastrointestinal Stromal Tumors|Breast Cancer|Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Malignant Carcinoid Syndrome|Islet Cell Adenoma|Neuroendocrine Tumors|Carcinoid Tumor
Phase 1: Oncology Solid Tumor Unspecified|Esophageal Cancer|Pancreatic Cancer|Lung Cancer|Colorectal Cancer|Lymphoma|Lymphoproliferative Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01386866 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-11-01 |
2019-03-19 |
Treatments |
|
| NCT00101894 | P1 |
Completed |
Colorectal Cancer |
2010-04-01 |
2020-10-26 |
||
| NCT00448786 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-12-01 |
2019-03-21 |
Treatments |
|
| NCT01235416 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-04-01 |
2019-03-19 |
Treatments |
|
| NCT00101907 | P1 |
Terminated |
Lung Cancer|Esophageal Cancer|Pancreatic Cancer |
2007-06-01 |
2019-03-21 |
||
| NCT00093873 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2006-02-01 |
2019-03-21 |
Treatments |
|
| 10G.30 | P2 |
Withdrawn |
Breast Cancer |
2015-09-01 |
2019-03-19 |
Treatments |
|
| CDR0000526256 | P2 |
Completed |
Neuroendocrine Tumors|Carcinoid Tumor|Malignant Carcinoid Syndrome|Islet Cell Adenoma|Gastrointestinal Cancer |
2014-10-01 |
2023-07-06 |
Primary Endpoints |
|
| GOG-0170L | P2 |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2013-07-01 |
2019-03-22 |
Treatments |
|
| NCT00360867 | P2 |
Terminated |
Oncology Solid Tumor Unspecified |
2012-07-01 |
2019-03-21 |
Treatments |
|
| AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Brest cancer | P2 |
Terminated |
Breast Cancer |
2012-05-30 |
2025-06-25 |
Treatments |
|
| 2005-004323-18 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2010-02-15 |
2022-03-12 |
Treatments |
|
| CIRG/TORI 010 | P2 |
Terminated |
Breast Cancer |
2009-02-01 |
2019-03-21 |
Treatments |
|
| ANZ 0601 / CIRG/TORI 010 | P2 |
Completed |
Breast Cancer |
2008-07-04 |
2025-03-12 |
Treatments |
|
| NCT00369070 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-04-23 |
2019-03-21 |
Treatments |
|
| 2005-001618-42 | P2 |
Completed |
Thyroid Cancer |
2007-03-09 |
2022-03-13 |
Treatments |
|
| NCT00094835 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2007-03-01 |
2020-10-26 |
Primary Endpoints |
|
| NCT00254267 | P2 |
Completed |
Gastrointestinal Stromal Tumors |
2007-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| NCT00121628 | P2 |
Completed |
Thyroid Cancer |
2006-11-01 |
2019-03-21 |
Treatments |
|
| 2004-002165-20 | P2 |
Completed |
Gastrointestinal Stromal Tumors |
2006-07-03 |
2022-03-12 |
Treatments |
|
| NCT00089960 | P2 |
Completed |
Gastrointestinal Cancer|Gastrointestinal Stromal Tumors |
2006-06-01 |
2019-03-21 |
Treatments |
|
| Asian Phase 3 Study | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2014-09-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| 2006-003784-32 | P3 |
Completed |
Pleural Effusion|Non-Small-Cell Lung Cancer|Pleural Cancer|Pericardial Effusion |
2012-12-13 |
2022-03-12 |
Treatments |
|
| NCT00460317 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2011-03-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| JapicCTI-121887 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
None |